SLONIN JONATHAN sold $71K of PCRX
SLONIN JONATHAN (Chief Medical Officer) sold 3,040 shares of Pacira BioSciences, Inc. (PCRX) at $23.23 on 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CMO’s open-market sale of 3,040 shares at $23.23 on 2026-08-17, with holdings after the transaction of 216,384 shares, under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor PCRX for sentiment effects from insider activity, but this specific disclosure is a routine 10b5-1 sale with limited fundamental implications.
What to watch
Insider sales often cluster around scheduled windows; without additional context (e.g., total compensation, prior sales, or concurrent buys), the trading signal is weak.
Background
The article is a SEC Form 4 insider transaction disclosure for Pacira BioSciences, Inc. (PCRX).
Ticker impact
Pacira BioSciences disclosed a Form 4 showing CMO SLONIN JONATHAN sold 3,040 shares at $23.23 on 2026-08-17 under a 10b5-1 plan.
Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.
The filing is a primary-source Form 4, but it reports a routine, pre-arranged open-market sale by an officer rather than new company performance, guidance, or events.
Market effects
Minimal. Insider selling in a single biotech name does not materially change sector fundamentals.
None indicated.
None indicated.
Counterpoint
The sale could be purely liquidity-driven and not reflective of business outlook, especially given the stated pre-arranged 10b5-1 plan.
Key entities
- issuerPacira BioSciences, Inc.
Company whose Form 4 insider transaction was filed.
- insiderSLONIN JONATHAN
Chief Medical Officer who sold shares.
